Table 2. Results of allogenic stem cell... | American Society of Hematology

Table 2.

Results of allogenic stem cell transplantation in patients with primary myelofibrosis (PMF).

	No. pts	Age	I/H risk, %	Regimen	TRM at 1 yr, %	CR, %	OS, %
*In 7 of 9 unrelated transplants, antithymocyte globulin (ATG) was not administered; cyclosporine A/ mycophenolate mofetil (CsA/MMF) was used as prophylaxis.
Abbreviations: I/H, ; TRM, transplantation-related mortality; CR, complete response; OS, overall survival: RIC, reduced-intensity conditioning
Guardiola et al⁴⁶^,⁵⁰	55	52	75	Myeloablative	27	40	14 (>45 y) at 5 yrs  62 (<45 y)
Dal et al⁴⁷	25	48	70	Myeloablative	48	33	41 2.9 y
Deeg et al⁴⁸	56	43	55	Myeloablative	32	53	58 2.8 y
Merup et al⁵²	14	43	71	Myeloablative	28	–	64 4.5 y
Devine at al⁵¹	4	56	100	RIC	0	100	100 3.5 y
Rondelli et al⁴	21	54	100	RIC	10	76	86 2.7 y
Kroger et al⁵³	21	53	76	RIC	16	75	84 2.2 y
Merup et al⁵²	8	54	87	RIC	12	–	87 4.5 y
Snyder, et al⁷¹	9*	54	89	RIC	45	–	55 2.7 y

	No. pts	Age	I/H risk, %	Regimen	TRM at 1 yr, %	CR, %	OS, %
*In 7 of 9 unrelated transplants, antithymocyte globulin (ATG) was not administered; cyclosporine A/ mycophenolate mofetil (CsA/MMF) was used as prophylaxis.
Abbreviations: I/H, ; TRM, transplantation-related mortality; CR, complete response; OS, overall survival: RIC, reduced-intensity conditioning
Guardiola et al⁴⁶^,⁵⁰	55	52	75	Myeloablative	27	40	14 (>45 y) at 5 yrs  62 (<45 y)
Dal et al⁴⁷	25	48	70	Myeloablative	48	33	41 2.9 y
Deeg et al⁴⁸	56	43	55	Myeloablative	32	53	58 2.8 y
Merup et al⁵²	14	43	71	Myeloablative	28	–	64 4.5 y
Devine at al⁵¹	4	56	100	RIC	0	100	100 3.5 y
Rondelli et al⁴	21	54	100	RIC	10	76	86 2.7 y
Kroger et al⁵³	21	53	76	RIC	16	75	84 2.2 y
Merup et al⁵²	8	54	87	RIC	12	–	87 4.5 y
Snyder, et al⁷¹	9*	54	89	RIC	45	–	55 2.7 y